Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) - Total Liabilities

Latest as of September 2025: ₩79.37 Billion KRW ≈ $53.79 Million USD

Based on the latest financial reports, Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) has total liabilities worth ₩79.37 Billion KRW (≈ $53.79 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Daishin Balance No.6 Special Purpose Acq to evaluate the company's liquid asset resilience ratio.

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd - Total Liabilities Trend (2020–2024)

This chart illustrates how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Daishin Balance No.6 Special Purpose Acq balance sheet assets.

Daishin Balance No.6 Special Purpose Acquisition Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Soke Degirmencilik AS
IS:SOKE
Turkey TL1.42 Billion
Vasta Platform Ltd
NASDAQ:VSTA
USA $2.07 Billion
Dallasnews Corp
NASDAQ:DALN
USA $37.75 Million
AFC Gamma Inc
NASDAQ:AFCG
USA $212.45 Million
TOPTEC Co. Ltd
KQ:108230
Korea ₩167.76 Billion
Richmond International Travel & Tours Co Ltd
TWO:2743
Taiwan NT$1.96 Billion
FIH Mobile Limited
F:FW3
Germany €2.36 Billion
Genohco Inc.
KQ:361390
Korea ₩42.57 Billion

Liability Composition Analysis (2020–2024)

This chart breaks down Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Daishin Balance No.6 Special Purpose Acq to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.16 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.80 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.45 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Daishin Balance No.6 Special Purpose Acquisition Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (2020–2024)

The table below shows the annual total liabilities of Daishin Balance No.6 Special Purpose Acquisition Co. Ltd from 2020 to 2024.

Year Total Liabilities Change
2024-12-31 ₩114.85 Billion
≈ $77.83 Million
-10.02%
2023-12-31 ₩127.65 Billion
≈ $86.50 Million
+23.00%
2022-12-31 ₩103.77 Billion
≈ $70.33 Million
+335.32%
2021-12-31 ₩23.84 Billion
≈ $16.15 Million
-6.78%
2020-12-31 ₩25.57 Billion
≈ $17.33 Million
--

About Daishin Balance No.6 Special Purpose Acquisition Co. Ltd

KQ:307750 Korea Drug Manufacturers - General
Market Cap
$78.21 Million
₩115.41 Billion KRW
Market Cap Rank
#20262 Global
#1085 in Korea
Share Price
₩2300.00
Change (1 day)
-1.71%
52-Week Range
₩1800.00 - ₩5540.00
All Time High
₩22045.88
About

KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support. It develops electronic mate… Read more